Video

Dr. Chaft on Considerations for Restarting Immunotherapy in Lung Cancer

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

Jamie E. Chaft, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, discusses considerations for restarting immunotherapy in patients with lung cancer.

It was once believed that all immune-related adverse events (IRAEs) were solely T-cell mediated. Now, it’s widely understood that not all IRAEs are created equal, says Chaft; some of these events may be T-cell mediated while others, such as thyroiditis, may be B-cell mediated. Others can experience cytokine-mediated events.

Since IRAEs are not created equal, they should be managed on an individualized basis, adds Chaft. Each event has a different level of severity and duration of impact on patients. IRAEs require a different level of consideration when determining whether to restart immunotherapy in a patient, explains Chaft.

These events need to be thoroughly evaluated and intervened upon to prevent harm to the patient. One of the most common interventions is either topical or systemic corticosteroids. Sometimes, steroid-sparing agents are used to prevent steroid-induced AEs, such as osteoporosis and gastritis, concludes Chaft. 

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the need for continued evaluation of prophylactic treatments like tocilizumab (Actemra) and antimicrobial measures for bispecific T-cell engagers, noting logistical and financial challenges and the importance of collaboration with community centers.